NIH Invention Disclosures, text of Federal Register announcement released February 22, 1996

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health

ACTION: Notice

The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in
accordance with 35 U.S.C. 207 to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for U.S. companies and may
also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the
indicated licensing specialist at the Office of Technology
Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone
301/496-7057; fax 301/402-0220). A signed Confidential
Disclosure Agreement will be required to receive copies of the
patent applications.

Azo Dye Derivatives Exhibiting Anti-HIV Activity, Pharmaceutical
Compositions Containing The Same And Methods For Using The Same
Haugwitz, R.D., Zalkow, L., Deutsch, H., Gruszecka-Kowalik, E.,
Asibal, C., Qazi, S. (NCI)
Filed 7 Jun 95
Serial No. 08/479,540 (FWC of 08/167,296)
Licensing Contact: Cindy K. Fuchs, 301/496-7735 ext 232
A method of obtaining substantially pure azo stilbenes
offers an important new tool for combating HIV infection. A
number of dyes have been shown to have anti-HIV activity;
however, it has previously not been possible to purify the anti-
HIV components of these compounds. This pure preparation of azo
stilbenes have a broad range of antiviral activity, including
anti-HIV activity. (portfolio: Infectious Diseases -
Therapeutics, antivirals, AIDS)

Amido Substituted Stilbenes And Related Compounds With In Vitro
Anti-HIV Activity
Haugwitz, R.D., Zalkow, L., Gruszecka-Kowalik, E., Burgess, E.
Filed 17 Feb 95
Serial No. 08/390,057
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268
Aroylaniline derivatives which exhibit antiviral activity,
methods for synthesizing these compounds, pharmaceutical
formulations containing these compounds, and methods for treating
viral infection are described in this invention. The
aroylaniline derivatives are capable of preventing the
replication of virus in a cell, such as human T-cell, without
staining the tissue. These compounds may effectively treat viral
infections of mammals, particularly human. A main target for
these compounds can be treatment against infections caused by
retroviruses such as HIV. (portfolio: Infectious Diseases -
Therapeutics, antivirals, AIDS)

Vaccine Against Hepatitis A Virus
Purcell, R.H., Ticehurst, J.R., Cohen, J.L., Emerson, S.U.,
Feinstone, S.M., Daemer, R.J., Gust, I.D. (NCI)
Filed 16 Jan 92
Serial No. 07/822,639 (Reissue of Serial No. 07/217,824; U.S.
Patent No. 4,894,228 issued 16 Jan 90)
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268
An attenuated hepatitis A virus (HAV) offers an important
new tool for the development of a protective vaccine.
Previously, immune serum globulin (ISG) is the only effective
vaccine for preventing HAV infection; however, ISG elicits only
low levels of neutralizing antibodies and, thus, requires
repeated doses. This attenuated HAV, which is a mutant of the
wild-type strain, elicits serum-neutralizing antibody production
in chimpanzees and is suitable for vaccine development.
(portfolio: Infectious Diseases - Vaccines, viral, non-AIDS)

A Method For Isolating Dendritic Cells
Cohen, P.A., Czerniecki, B.J., Carter, C., Fowler, D.H., Kim, H. (NCI)
Filed 27 Jan 95
Serial No. 08/379,227
Licensing Contact: Stephen Finley, 301/496-7735 ext 215
Antigen presenting cells (APCs) are cells that are involved in the
presentation of antigens to the immune system. APCs can stimulate the immune
system -- T lymphocytes -- to fight infections, including HIV and some forms
of cancer. A wide variety of cells have the capability to act as APCs,
including monocytes, macrophages, B cells, and dendritic cells; however,
extensive research has indicated that the most potent antigen presenting cell
is the dendritic cells. Previous methods for isolating dendritic cells have
relied on either the isolation of bone marrow precursor cells from blood
followed by stimulation to form dendritic cells, or the collection of
precommitted cells from peripheral blood. Both of these methods have
drawbacks: the necessity to treat the patient with cytokines to increase the
number of precursor cells in the blood or techniques that lead to physical
trauma of the dendritic cells. This invention embodies a method to isolate
dendritic cells from blood in which leukapheresis is employed as a preliminary
step to enrich for precursor cells in a patient without the requirement for
cytokine treatment followed by countercurrent centrifugal elutriation. The
purity of the cells isolated is much greater than any other known method.
(portfolio: Central Nervous System - Research Tools and Reagents)

Beckner, M.E., Liotta, L.A. (NCI)
Filed 25 Jun 93
Serial No. 08/083,945 (CIP of 07/827,043)
Licensing Contact: Susan Rucker, 301/496-7056 ext 245
AAMP-1, a novel protein that has human cell adhesion properties has been
characterized. Peptides derived from that protein have been shown to exhibit
heparin-binding and cell-adhesive properties. The heparin-binding properties
of the peptides may be useful for the treatment of conditions in which the
presence or absence of heparin and/or heparin-sulfate needs to be regulated.
These conditions could include heparinization to prevent blood clotting and
possibly inflammatory, immune, or neoplastic disorders, and wound-healing in
human patients. The cell-adhesion properties of the peptides may be useful
for mediating cell-cell and cell-substrate adhesion. These properties might
be particularly useful for producing materials for use in prosthetic
devicesūcell adhesion to a prosthetic device could potentially be controlled
by regulating the presence or absence of heparin in the bodily system of the
patient receiving a prosthetic device made with the peptides. The peptides
retain their properties following crystallization, and the crystallized
peptides are heat-stable and not inactivated by solvents. The small size and
enhanced stability and processability of the crystalline peptides versus the
native AAMP-1 protein suggest that the peptides will be more useful
therapeutic agents and better raw materials for device fabrication than the
native protein. (portfolio: Cancer - Diagnostics, in vitro, other; Cancer -
Therapeutics, biological response modifiers)